Monoamine oxidases (MAO) influence the monoamine levels in brain by virtue of their role in neurotransmitter breakdown. MAO B is the predominant form in glial cells and in platelets. MAO B structure, function and kinetics are described as a background for the effect of alterations in its activity on behavior. The need to inhibit MAO B to combat decreased brain amines continues to drive the search for new drugs. Reversible and irreversible inhibitors are now designed using data-mining, computational screening, docking and molecular dynamics. Multi-target ligands designed to combat the elevated activity of MAO B in Alzheimer's and Parkinson's Diseases incorporate MAO inhibition (usually irreversible) as well as iron chelation, antioxidant or neuroprotective properties. The main focus of drug design is the catalytic activity of MAO, but the imidazoline I 2 site in the entrance cavity of MAO B is also a pharmacological target. Endogenous regulation of MAO B expression is discussed briefly in light of new studies measuring mRNA, protein, or activity in healthy and degenerative samples, including the effect of DNA methylation on the expression. Overall, this review focuses on examples of recent research on the molecular aspects of the expression, activity, and inhibition of MAO B.
Introduction
The monoamine neurotransmitters dopamine, serotonin, and noradrenaline influence neuronal signaling in the brain. Changes in the monoamine system are associated with depression, addiction, aggression, and amine levels decrease in neurodegenerative diseases.
The balance between the synthetic enzymes and the breakdown enzymes sets the overall level of amines in the brain. The amount of the neurotransmitter amines available for signaling is strongly dependent upon the reuptake carriers (DAT, SERT, NET) and on the vesicular transporter (VMAT) driven by the proton gradient generated by the vesicular ATPase. Neurotransmitter release is controlled by signaling pathways and modulated by pre-synaptic auto-receptors. The post-synaptic effect of the neurotransmitters depends on specific families of receptors (D 1-5 , 5-HT 1-7 and adrenergic receptors, and the related TAAR1 for trace amines), most of which are G-protein coupled receptors (GPCRs) -see Beaulieu et al. (2015) and McCorvy and Roth (2015) , and the IUPHAR database of the genetic and functional properties of receptors (http://www.guidetopharmacology.org/) (Sharman et al., 2011) .
MAO, as the major metabolic enzyme for the deactivation of the monoamine neurotransmitters, is a key target in neuropsychopharmacology. Its inhibitors, used as antidepressant drugs for over 50 years, have been shown to raise brain amine levels. The observation that inhibition of MAO increases monoaminergic function has supported a long-running drug discovery effort to find novel drugs that inhibit MAO to treat mood and degenerative disorders, including depression, aggression, schizophrenia, hyperactivity, Parkinson's Disease (PD), and Alzheimer's Disease (AD) (Oreland, 2004; Murphy et al., 2006; Oreland et al., 2007; Fisar et al., 2010; Bortolato and Shih, 2011; Song et al., 2013) . In current efforts to discover compounds to combat neurodegeneration in PD and AD, MAO inhibition is a key feature in multi-target designed ligands (MTDL) that are intended to help spare the decreasing levels of neurotransmitters (Ramsay, 2012; Zheng et al., 2012; Bautista-Aguilera et al., 2014) . A further benefit of inhibiting MAO is the decreased production of ammonia and hydrogen peroxide that accompany amine oxidation, thus reducing oxidative stress (Kaludercic et al., 2014; Ooi et al., 2015) .
MAO iso-enzymes are important because their activity sets the monoaminergic tone of the brain. The interest in drug design to increase monoamine levels is reflected in a constant stream of reviews. Several reviews in the last 5 years provide the wider background to MAO (Bortolato and Shih, 2011; Youdim and Reiderer, 2011; Ramsay, 2012; Song et al., 2013; Fowler et al., 2015) This review will include key references for the established facts but focus on examples of recent research on the expression, activity and inhibition of MAO B.
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